^
    Back
    Association details:
    Biomarker:MSI-H/dMMR + PD-L1 expression
    Cancer:Neuroendocrine Tumor
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Cancer Med
    Title:

    PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer

    Published date:
    06/02/2021
    Excerpt:
    The IHC results of PD-L1, PARP1, and MMRs suggested that NECC was the target of immunotargeted therapy. Our case confirmed that immune checkpoint therapy was effective in patients with PD-L1 positive and MMRs loss.
    DOI:
    https://doi.org/10.1002/cam4.4034